AVID100 in Advanced Epithelial Carcinomas

Summary

Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is available, will be entered into this Phase 1a/2a, multicenter, open-label, dose-escalation, cohort study of AVID100. Phase 2a will include evaluation of patient with EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer

Timeline

Start

2017-02-01

Primary completion

2020-11-28

Completion

2021-01-30

Outcome

Outcome not reported

Stopped: “lack of efficacy”

Drugs

Indications